Evidence map›Paper›PMID 36781931›Full record

ArticleScientific reports2023

Contribution of vitamin D

Annamaria D'Alessandro, Domenico Ciavardelli, Anna Pastore, Santina Lupisella, Rosa Carmela Cristofaro, Giovina Di Felice, Roberta Salierno, Marco Infante, Alberto De Stefano, Andrea Onetti Muda and 2 more

Erratum issuedOpen access · goldAbstract readMulticenter Study
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Annamaria D'Alessandro *Clinical Biochemistry Laboratory, IRCCS Bambino Gesù Children's Hospital, 00165, Rome, Italy.
Domenico Ciavardelli *School of Medicine, University "Kore" of Enna, 94100, Enna, Italy.
Anna Pastore *Research Unit of Diagnostical and Management Innovations, IRCCS Bambino Gesù Children's Hospital, 00165, Rome, Italy. anna.pastore@opbg.net.ORCID 0000-0002-0990-9419
Santina LupisellaClinical Biochemistry Department, Tor Vergata University Hospital (PTV), Rome, Italy.
Rosa Carmela CristofaroClinical Biochemistry Laboratory, IRCCS Bambino Gesù Children's Hospital, 00165, Rome, Italy.
Giovina Di FeliceClinical Biochemistry Laboratory, IRCCS Bambino Gesù Children's Hospital, 00165, Rome, Italy.
Roberta SaliernoClinical Biochemistry Department, Tor Vergata University Hospital (PTV), Rome, Italy.
Marco InfanteDepartment of Systems Medicine, Diabetes Research Institute Federation (DRIF), Tor Vergata University, Rome, Italy.
Alberto De StefanoPsychiatric Unit Department of Systems Medicine, Tor Vergata University, Rome, Italy.
Andrea Onetti MudaResearch Unit of Diagnostical and Management Innovations, IRCCS Bambino Gesù Children's Hospital, 00165, Rome, Italy.
Maria Morello *Clinical Biochemistry Department, Tor Vergata University Hospital (PTV), Rome, Italy.
Ottavia Porzio *Clinical Biochemistry Laboratory, IRCCS Bambino Gesù Children's Hospital, 00165, Rome, Italy.
University of Rome Tor Vergata · ITBambino Gesù Children's Hospital · ITUniversità degli Studi di Enna Kore · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), was declared a global pandemic by the World Health Organization (WHO) on March 2020, causing unprecedented disease with million deaths across the globe, mostly adults. Indeed, children accounted for only a few percent of cases. Italy was the first Western country struck by the COVID-19 epidemic. Increasing age, which is one of the principal risk factors for COVID-19 mortality, is associated with declined glutathione (GSH) levels. Over the last decade, several studies demonstrated that both vitamin D (VD) and GSH have immunomodulatory properties. To verify the association between VD, GSH and the outcome of COVID-19 disease, we conducted a multicenter retrospective study in 35 children and 128 adult patients with COVID-19. Our study demonstrated a hypovitaminosis D in COVID-19 patients, suggesting a possible role of low VD status in increasing the risk of COVID-19 infection and subsequent hospitalization. In addition, we find a thiol disturbance with a GSH depletion associated to the disease severity. In children, who fortunately survived, both VD and GSH levels at admission were higher than in adults, suggesting that lower VD and thiols levels upon admission may be a modifiable risk factor for adverse outcomes and mortality in hospitalized patients with COVID-19.

Indexed as

COVID-19Vitamin D DeficiencyAdultChildCholecalciferolGlutathioneHumansItalyRetrospective StudiesSulfhydryl CompoundsVitamin DVitaminsCholecalciferolGlutathioneSulfhydryl CompoundsVitamin DVitamins

Identifiers

PMID36781931
PMCPMC9925220
OpenAlexW4320482415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.